Mumbai: The Income Tax Department has sent a Rs.773.44 crore extra tax demand to Cipla, a well-known pharmaceutical corporation. According to a notification made to the stock markets on Tuesday, this demand—which includes interest—relates to assessment years between 2015–16 and 2022–23.
Cipla claims that this increased tax demand resulted from assessment and reassessment directives issued by the Income Tax Authority on July 12, 2024. The increased demand is a result of many disallowances, which include the disallowance of certain expenditures under section 37(1), the weighted deduction under section 35(2AB), and the short deduction under section 80IE of the Income Tax Act. The deduction of earnings and gains from building, maintaining, and running infrastructural facilities, research and development costs, and business or professional charges are the key areas of disallowances.
Cipla says that the requests made by the tax authorities are “not tenable” in accordance with the law, expressing its disagreement with the authority’s accusations. Citing compelling factual and legal arguments to back its stance, the corporation plans to file an appeal against the Income Tax Department’s ruling. Cipla has reassured stakeholders that this order will not have a material effect on company operations or financial situation.
The firm is confident in its position since it thinks there is insufficient legal support for the tax demands. Through the appeals process, Cipla is dedicated to supporting its stance and making sure that it complies with all legal and regulatory requirements while safeguarding its financial interests.
This event comes after an earlier one on February 6, 2023, when Cipla revealed that searches had been carried out at certain of company offices and manufacturing facilities by officials from the Income Tax Department. The department’s more extensive examination of the business’s financial procedures included the searches.
Cipla is continuing to concentrate on its commercial operations in spite of the tax demand. On July 26, 2024, the business is expected to release its quarterly results for Q1FY25. Amidst the ongoing tax issue, stakeholders and investors are eagerly anticipating these data to assess the company’s operational performance and financial standing.
In the stock market, Cipla’s shares closed at Rs.1507.50 on the Bombay Stock Exchange (BSE) on Tuesday, a slight decrease of 0.56%. By comparison, the benchmark Sensex saw a slight increase of 0.06%, ultimately closing at 80,716.55 points. This inconsistent reaction from the market underscores investors’ cautious attitude, weighing the possible effects of the tax demand against Cipla’s strong market position and operational stability.
Although Cipla faces a difficulty as a result of the increased tax demand, the company appears well-equipped to overcome this obstacle based on its proactive approach to disputing the claim and its dedication to upholding financial stability. The results of the appeals process and its consequences for Cipla’s future financial and operational performance will be closely watched by stakeholders and investors.
SOURCE
ECONOMIC TIMES
